Evidence map›Paper›PMID 34790045›Full record

ArticleInternational journal of medical sciences2021

Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations.

Yanke Yu, Jian Lin, Chieko Muto, Yinhua Li, Yuko Mori, Rajendar K Mittapalli, Susanna Tse, Jian Liu, Bei Kang Ge, Jing Liu

Abstract read
In one paragraph

Article in International journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanke YuPfizer Inc, La Jolla, CA, USA.
Jian LinPfizer Inc, Groton, CT, USA.
Chieko MutoPfizer R&D Japan, Tokyo, Japan.
Yinhua LiPfizer R&D Japan, Tokyo, Japan.
Yuko MoriPfizer R&D Japan, Tokyo, Japan.
Rajendar K MittapalliPfizer Inc, La Jolla, CA, USA.
Susanna TsePfizer Inc, Groton, CT, USA.
Jian LiuPfizer Investment Co., LTD, China.
Bei Kang GePfizer Investment Co., LTD, China.
Jing LiuPfizer Inc, Groton, CT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective for the present analyses was to evaluate the utility of physiologically-based pharmacokinetic (PBPK) modeling for prediction of the pharmacokinetics (PK) in Chinese and Japanese populations with a panel of Pfizer internal compounds. Twelve compounds from Pfizer internal development pipeline with available Westerner PK data and available PK data in at least one of the subpopulations of Japanese and Chinese populations were identified and included in the current analysis. These selected compounds represent various elimination pathways across different therapeutic areas. The Simcyp

Indexed as

Metabolic Clearance RateModels, BiologicalPharmacokineticsAsian PeopleChinaComputer SimulationHumansJapanPredictive Value of TestsPrognosisChineseEthnic PKJapaneseModeling & SimulationPBPK

Identifiers

PMID34790045
PMCPMC8579302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.